This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saadi, S. Articles by Platt, J. L. Search for Related Content PubMed PubMed Citation Articles by Saadi, S. Articles by Platt, J. L. Related Collections Endothelium/vascular type/nitric oxide Other Vascular biology Gene expression Genetically altered mice

(Circulation. 2000;101:1867.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Endothelial Cell Activation by Pore-Forming Structures

Pivotal Role for Interleukin-1

Soheyla Saadi, PhD; Robert A. Holzknecht, BS; Christian P. Patte, BS; Jeffrey L. Platt, MD

From the Department of Surgery (S.S., R.A.H.) and Departments of Pediatrics and Immunology (C.P.P., J.L.P.), Mayo Clinic, Rochester, Minn.

Correspondence to Soheyla Saadi, PhD, Mayo Clinic, Medical Science 2–66, Rochester, MN 55905. E-mail saadi.soheyla{at}mayo.edu

Background—Interaction of complement with endothelial cells (ECs) underlies the development of inflammation and coagulation in disease. Assembly of the membrane attack complex (MAC) of complement on EC membrane, like stimulation with cytokines, upregulates tissue factor and cyclooxygenase-2 but does so via the intermediary action of IL-1. We asked whether the MAC activates porcine aortic and microvascular ECs in a global manner by this mechanism and whether this mechanism is used by membrane pore-forming structures.

Methods and Results—Exposure of ECs to complement caused upregulation of mRNAs for E-selectin, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, I-B, interleukin (IL)-1, IL-1ß, IL-8, and plasminogen activator inhibitor-1 over a period of 6 hours. The expression of these genes was not a primary response to stimulation, however, because IL-1 receptor antagonist inhibited expression of these genes. Activation of ECs by complement depended on the autocrine action of IL-1, because complement-mediated EC activation was inhibited by anti–IL-1 antibodies. Melittin and mastoparan, amphiphilic pore-forming peptides like the MAC, induced E-selectin through intermediary action of IL-1.

Conclusions—These findings suggest that transmembrane pore-forming proteins, as a class of molecules, activate ECs through the autocrine effects of IL-1.

Key Words: pore-forming peptides • endothelium • interleukin-1

This article has been cited by other articles:

				G. J. Brunn, S. Saadi, and J. L. Platt Constitutive Repression of Interleukin-1{alpha} in Endothelial Cells Circ. Res., April 11, 2008; 102(7): 823 - 830. [Abstract] [Full Text] [PDF]

				L. R. La Bonte, G. Davis-Gorman, G. L. Stahl, and P. F. McDonagh Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1282 - H1290. [Abstract] [Full Text] [PDF]

				D. A. Rao, K. J. Tracey, and J. S. Pober IL-1{alpha} and IL-1beta Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response J. Immunol., November 15, 2007; 179(10): 6536 - 6546. [Abstract] [Full Text] [PDF]

				P. Redecha, R. Tilley, M. Tencati, J. E. Salmon, D. Kirchhofer, N. Mackman, and G. Girardi Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury Blood, October 1, 2007; 110(7): 2423 - 2431. [Abstract] [Full Text] [PDF]

				E. Simeoni, J. Dudler, S. Fleury, J. Li, M. Pagnotta, M. Pascual, L. K. von Segesser, and G. Vassalli Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 222 - 228. [Abstract] [Full Text] [PDF]

				K. J. Tinckam and A. Chandraker Mechanisms and Role of HLA and non-HLA Alloantibodies Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 404 - 414. [Abstract] [Full Text] [PDF]

				G. J. Brunn, S. Saadi, and J. L. Platt Differential Regulation of Endothelial Cell Activation by Complement and Interleukin 1{alpha} Circ. Res., March 31, 2006; 98(6): 793 - 800. [Abstract] [Full Text] [PDF]

				C. A. Koch, A. Kanazawa, R. Nishitai, B. E. Knudsen, K. Ogata, T. B. Plummer, K. Butters, and J. L. Platt Intrinsic Resistance of Hepatocytes to Complement-Mediated Injury J. Immunol., June 1, 2005; 174(11): 7302 - 7309. [Abstract] [Full Text] [PDF]

				D. Turnberg, M. Botto, M. Lewis, W. Zhou, S. H. Sacks, B. P. Morgan, M. J. Walport, and H. T. Cook CD59a Deficiency Exacerbates Ischemia-Reperfusion Injury in Mice Am. J. Pathol., September 1, 2004; 165(3): 825 - 832. [Abstract] [Full Text] [PDF]

				C. A. Koch, Z. I. Khalpey, and J. L. Platt Accommodation: Preventing Injury in Transplantation and Disease J. Immunol., May 1, 2004; 172(9): 5143 - 5148. [Abstract] [Full Text] [PDF]

				S. Saadi, T. Takahashi, R. A. Holzknecht, and J. L. Platt Pathways to Acute Humoral Rejection Am. J. Pathol., March 1, 2004; 164(3): 1073 - 1080. [Abstract] [Full Text] [PDF]

				D. Turnberg, M. Botto, J. Warren, B. P. Morgan, Mark. J. Walport, and H. T. Cook CD59a Deficiency Exacerbates Accelerated Nephrotoxic Nephritis in Mice J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2271 - 2279. [Abstract] [Full Text] [PDF]

				S. SAADI, L. E. WRENSHALL, and J. L. PLATT Regional manifestations and control of the immune system FASEB J, June 1, 2002; 16(8): 849 - 856. [Abstract] [Full Text] [PDF]

				J. E. Jordan, M. C. Montalto, and G. L. Stahl Inhibition of Mannose-Binding Lectin Reduces Postischemic Myocardial Reperfusion Injury Circulation, September 18, 2001; 104(12): 1413 - 1418. [Abstract] [Full Text] [PDF]

				R. Lekowski, C. D. Collard, W. R. Reenstra, and G. L. Stahl Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation Protein Sci., February 1, 2001; 10(2): 277 - 284. [Abstract] [Full Text]